Deflazacort 18 MG Oral Tablet [Emflaza] — RxCUI 1870956
RxNorm drug concept · Semantic branded drug
RxCUI 1870956
Semantic branded drug · SBD
● Current RxNorm concept 5 FDA products
5 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1870956
Official nameDeflazacort 18 MG Oral Tablet [Emflaza]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEmflaza 18 MG Oral Tablet
FDA products mapped5
Package NDCs mapped5
Reported Medicaid activity (SDUD)11,218 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Deflazacort: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Deflazacort is used to treat Duchenne muscular dystrophy (DMD), a genetic disease that causes muscles to weaken and break down over time. It's a corticosteroid — a type of anti-inf...
- Yes — several brands, including Emflaza, Jaythari, and Kymbee tablets, can be crushed and mixed immediately with applesauce if swallowing a whole tablet is difficult. The oral susp...
- Can my child take the tablet if they have trouble swallowing pills?
- Many children on deflazacort develop a rounder, puffier face (sometimes called a 'moon face'), gain weight, grow more body hair, and get more frequent infections — these are common...
🕸️ Concept Web — How Deflazacort 18 MG Oral Tablet [Emflaza] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Deflazacort 18 MG Oral Tablet [Emflaza]
RxCUI 1870956 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Deflazacort
22396IN
-
Deflazacort
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Emflaza
1870945BN
-
Emflaza
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Deflazacort Oral Tablet
371693SCDF -
Deflazacort Oral Product
1157200SCDG -
Deflazacort Pill
1157201SCDG -
Deflazacort Oral Tablet [Emflaza]
1870947SBDF -
Emflaza Oral Product
1870948SBDG -
Emflaza Pill
1870949SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Deflazacort Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Deflazacort 18 MG Oral Tablet
1870954SCD -
Deflazacort 18 MG
1870953SCDC -
Deflazacort 18 MG [Emflaza]
1870955SBDC
-
Deflazacort 18 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Deflazacort 18 MG Oral Tablet
SCD · 1870954 -
Deflazacort 18 MG
SCDC · 1870953 -
Deflazacort Oral Tablet
SCDF · 371693 -
Deflazacort Oral Product
SCDG · 1157200 -
Deflazacort Pill
SCDG · 1157201
Brand-Name Concepts
-
Deflazacort 18 MG [Emflaza]
SBDC · 1870955 -
Deflazacort Oral Tablet [Emflaza]
SBDF · 1870947 -
Emflaza Oral Product
SBDG · 1870948 -
Emflaza Pill
SBDG · 1870949 -
Emflaza
BN · 1870945
📦 FDA Products & Package NDCs
5 products · 5 package NDCs
5 package NDCs map to RxCUI 1870956 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 52856-0501-01 | 100 TABLET in 1 BOTTLE (52856-501-01) | EMFLAZA | PTC Therapeutics, Inc. | 2018-09-10 |
| 52856-0502-03 | 30 TABLET in 1 BOTTLE (52856-502-03) | EMFLAZA | PTC Therapeutics, Inc. | 2018-09-10 |
| 52856-0503-03 | 30 TABLET in 1 BOTTLE (52856-503-03) | EMFLAZA | PTC Therapeutics, Inc. | 2018-09-10 |
| 52856-0504-03 | 30 TABLET in 1 BOTTLE (52856-504-03) | EMFLAZA | PTC Therapeutics, Inc. | 2018-09-10 |
| 52856-0505-22 | 13 mL in 1 BOTTLE (52856-505-22) | EMFLAZA | PTC Therapeutics, Inc. | 2019-08-30 |
Observed labelers:
PTC Therapeutics, Inc. (5)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.